Screening for Celiac Disease Using Anti Tissue Transglutaminase in Patients with Esophageal SCC between 2004 and 2009

Document Type : Original Article


1 Gastroenterologist, Department of Gastroenterology and Hepatology, Mashhad University of Medical Sciences, Mashhad, Iran

2 Oncologist, Department of Radiotherapy and Oncology, Mashhad University of Medical Sciences, Mashhad, Iran

3 Anatomo Clinical pathologist, Razavi Hospital, Mashhad, Iran

4 Community Medicine Specialist, Department of Epidemiology & Social Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

5 Internal Medicine Specialist, Department of Internal Medicine, Azad University of Medical Sciences, Mashhad, Iran

6 Student of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

7 Gastroenterologist, Gastroenterology and Hepatology, Nayshabour Faculty of Medical Sciences, Nayshabour, Iran


Introduction: Esophageal Squamous-Cell Carcinoma (SCC) is one of the most common malignancies in Iran. To reduce the incidence of esophageal SCC, it is important to recognize the controllable risk factors and prevent them. Celiac disease is widely known as a possible risk factor for esophageal SCC.  Thus, we decided to assess the frequency of celiac disease in esophageal SCC patients in North east of Iran in order to suggest correlation between two diseases.
Materials and Methods: In a Cross-sectional study one hundred and forty-three cases of esophageal SCC were examined for anti tissue transglutaminase antibody (anti-tTG) between the years 2004 and 2009 in Ghaem and Omid Hospitals of Mashhad University of Medical Sciences, Iran. The enzyme-linked immunosorbent assay was the test of choice in this study since it provides the sensitivity and specificity needed for the diagnosis and screening of celiac disease. The results of this test were compared with those of the control group which were compatible in terms of sex and age. Data were analyzed through SPSS software and statistical analysis such as x2, exact x2 and T-test.
Results:19.6% patients (SCC) had positive anti-tTG (>20) which was significantly different to 7.9% in control group (p -value=0.005). Comparing age groups of patients for positive anti_tTG using exact x square test showed significant difference in patients with

Conclusion: There seems to be a correlation between positive anti_tTG and esophageal SCC; that is to say, celiac disease might play a role in the earlier manifestations of esophageal SCC.


1.  Fleischer D, Lawrence S; tumors of the esophagus. In: Sleisenger and Fordtran`s Gastrointestinal and liver disease. 9th ed. Philadelphia: Saunders press; 2010. p. 745-770.
 3. P.U. Cook-Mozaffari, F. Azordegan, N.E. Day, A.Ressicaud, C. Sabai, B. Aramesh: Oesophageal cancer studies in the caspitan littoral of Iran: results of a case-control study. Br J Cancer, 1979; 39: 293-309.
 4. A. Pourshams, Saadatian-Elahi M, Nouraie M, Malekshah AF, Rakhshani N, Salahi R, et al.  Golestan cohort study of oesophageal cancer: feasibility and first results. Br J Cancer, 2005. 92: 176-81.
 5. Enzyinger PC, Mayer RJ. Esophageal cancer. NEJM 2003; 349; 23: 2241-52.
 6. Lee, Y.C., Marron M, Benhamou S, Bouchardy C, Ahrens W, Pohlabeln H, et al. Active and involuntary tobacco smoking and upper aerodigestive tract cancer risks in a multicenter case-control study. Cancer Epidemiol Biomarkers Prev, 2009. 18: 3353-61.
 7. Freedman, N.D., Abnet CC, Leitzmann MF, Mouw T, Subar AF, Hollenbeck AR, Schatzkin A.  A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol, 2007; 165: 1424-33.
 8. Parkin, D.M. Tobacco-attributable cancer burden in the UK in 2010. Br J Cancer, 2011; 105: 6-13.    
 9. Lee, C.H., Lee JM, Wu DC, Hsu HK, Kao EL, Huang HL, et al. Independent and combined effects of alcohol intake, tobacco smoking and betel quid chewing on the risk of esophageal cancer in Taiwan. Int J Cancer, 2005; 113: 475-82.   
 10. Zendehdel K, Nyrén O, Edberg A, Ye W: Risk of esophageal adenocarcinoma in    achalasia patients, a retrospective cohort study in Sweden. Am J Gastroenterol  2007; 102:1-5.
 11. Ghavamzadeh A, Moussavi A, Jahani M, Rastegarpanah M, Iravani M.  Esophageal cancer in Iran. Semin Oncol 2001; 28:153-157.
 12.  Askling J, Linet M, Gridley G, Halstensen TS.    Cancer incidence in population–based cohort of individuals hospitalized with celiac disease. Gastroentrology 2002; 123: 1428-35.   
 13. Frrgusen A, Kingstone K. Celiac disease and malignancies. Acta Pediatr. Suppl. 1998; 412: 78-81. 
 14. Lightdale CJ, Winawer SJ. Screening diagnosis and Staging of esophageal cancer. Semin oncology 1984; 11: 101-12.
 15. West J, Logan RF, Hill PG, Lloyd A, Lewis S, Hubbard R, et al. Seroprevalence, correlates, and characteristics of undetected coeliac disease in England. Gut 2003; 52:960-965.      
 16. Peter H.R. Green, M.D.Celiac Disease.  Et al. Engl J Med 2007; 357: 1731-1743.       
 17. Rostami Nejad M, Rostami K, Emami M, Zali M, Malekzadeh R."Epidemiology of Celiac Disease in Iran: A Review": MEJDD 2011; 3: 5-12.  
 18. Malek zadeh R. Shakeri R. Celiac disease in Iran.TUMJ 2007 May; 65(2):1-11.
 19. Saberi-Firouzi M, Omrani GR, Nejabat M, Mehrabani D, Khademolhosseini F. Prevalence of celiac disease in Shiraz, Southern Iran. Saudi J Gastroenterol 2008; 14: 135-8.
 20. Khoshnia M, Pourshams A. Celiac disease in Gonbad-Kavoos: Govaresh autumn 2005; 10: 131-3.
 21. Tirgar-Fakheri H, MalekzadehR, Akbari MR, Sotoudeh M. Prevalence of Celiac disease in north of Iran: Screening of an adult population in Sari. J Gorgan Uni Med Sci; 2004 ; 6: 94-100.
 22. Akbari MR, Mohammadkhani A, fakheri H.  Screening of the adult population in Iran for celiac disease: comparison of the tissue transglutaminase antibody and anti-endomysial antibody tests. Eur J Gastroenterol Hepatol 2006; 18: 1181-6.
 23.Rampertab SD, Pooran N. Trends in the presentation of celiac disease. Am J Med.2006; 119:355.
 24. Freeman HJ. Malignancy in celiac disease. J. New Gastroenterol 2009; 15: 1581-1583
 25. West J, Logan RF. Malignancy and mortality in people with celiac disease: population based cohort study. BMJ 2004; 329:716-9.
 26.Card TR, West J. Risk of malignancy in diagnosed celiac disease: a 24-year prospective, population-based, cohort study. Aliment Pharmacol Ther. 2004; 20: 769-75.
 27. Green pH, Fleischauer AT, Bhagat G, Goyal R. Risk of malignancy in patients with celiac disease. Am J Med 2003; 115: 191-5.
 28. Collins SM, Hamilton JD. Small-bowel Malabsorption and gastrointestinal malignancy. Radiology 1996; 126: 603-9.
 29. Holmes GK, Prior P. Malignancy in celiac disease-effect of a gluten free diet.Gut 1989; 30: 333-338.
 30. Brottveit M, Lundin KE.  Cancer risk in celiac disease. Tidsskr Nor Laegeforen 2008; 128: 2312-5.